Inhibitor

(redirected from PDE inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Legal.
Related to PDE inhibitor: phosphodiesterase type 5 inhibitors, PDE5

inhibitor

[in′hib·əd·ər]
(aerospace engineering)
A substance bonded, taped, or dip-dried onto a solid propellant to restrict the burning surface and to give direction to the burning process.
(chemistry)
A substance which is capable of stopping or retarding a chemical reaction; to be technically useful, it must be effective in low concentration.

Inhibitor

 

a circuit having m + n inputs and a single output, at which a signal can appear only when there are no signals on the m inputs (inhibiting). The other n inputs (principal) form one of the two logic connections, “AND” or “OR.” Inhibitors are used extensively in computers. They are very often understood to be a circuit having a single principal input and a single inhibiting input. A signal appears at the output of such a circuit when a signal is present on the principal input but there is none on the inhibiting input. Such an inhibitor is called an anticoincidence gate; its conventional representation is given in Figure 1.

Figure 1. Block diagram of an anticoincidence gate (inhibitor) with m — 1 and n 1:(A) principal input, (Q) inhibiting input, (Ga) anticoincidence gate

inhibitor

A substance added to paint to retard drying, skinning, mildew growth, etc. Also see corrosion inhibitor, inhibiting pigment, drying inhibitor.
References in periodicals archive ?
Which areas of PDE inhibitor development have high priority research needs?
PDE inhibitors and NO positively affect separate targets in the erectile process.
Exposure of these cells to A2A agonists and specific PDE inhibitors results in rapid synergistic inhibition of proliferation and induction of apoptosis.
It expands the use of PDE inhibitors for erectile dysfunction by allowing for additional routes of administration across mucous membranes.
PARTNERED PROGRAMS UNPARTNERED PROGRAMS Aventis Agreement (Respiratory) IPL512,602 - Asthma & Allergic Rhinitis IPL550,260 - Inflammation IPL12 (series) - Respiratory IPL576,092 - Ocular/derm H1/NK1(series) - Allergic Rhinitis IPL99 (series) - Inflammation Helicon Agreement (Learning & Memory) PDE Inhibitors - PDE Inhibitors - Enhancement of Learning Inflammation & Memory
The estimated 5-6 million patients who do not respond or cease to respond to PDE inhibitors are candidates for treatment with injectable prostaglandin E1 (PGE1; also known as alprostadil) sterile power for injection products such as CAVERJECT(TM) (Pfizer/Pharmacia) and EDEX(TM) (Schwarz Pharma) or other more invasive means.
Commonly known NO donor compounds include nitroglycerin and sodium nitroprusside; PDE inhibitors include sildenafil (Viagra(TM), Pfizer), vardenafil (Levitra(TM), Bayer) and tadalafil (Cialis(TM), Lilly/ICOS).
Lilly ICOS LLC today announced that the UK Court of Appeal in London upheld a lower court's ruling that found Pfizer's entire "method of use" patent for PDE inhibitors to treat erectile dysfunction (ED) was invalid.
Nasdaq: VVUS) today announced that the UK Court of Appeal in London, England has upheld a lower court's ruling, which found Pfizer's entire patent on use of PDE inhibitors to treat erectile dysfunction (ED) to be invalid.
Lilly ICOS LLC today announced that the Opposition Division of the European Patent Office (EPO) declared invalid Pfizer's "method of use" patent EP702555 for PDE inhibitors, including sildenafil.